Novel Turbidimetric Immunoassay Evaluated for Fecal Calprotectin
|
By LabMedica International staff writers Posted on 28 Sep 2016 |
|
Image: The BS-380 automatic biochemistry analyzer (Photo courtesy of Mindray).
Calprotectin is a multifunctional protein that plays an important role in the diagnosis and follow-up of inflammatory bowel disease and high levels of calprotectin in stool samples are associated with inflammation of the intestinal tract.
Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD, but the problem with most of the fecal calprotectin assays is the rather long test-turnaround times, before the results are available to the physician.
Scientists at Uppsala University (Sweden) optimized a particle enhanced turbidimetric immunoassay (PETIA) for fecal calprotectin and validated the assay for two clinical autoanalyzers using routine fecal samples. They compared the PETIA with a commercial enzyme-linked immunosorbent assay (ELISA), known as the Bühlmann fCAL ELISA (Bühlmann Laboratories, Schönenbuch, Switzerland). This new latex based turbidimetric calprotectin assay applies particles coated with anti-human calprotectin (MRP8/14) antibodies: the agglutination is proportional to the calprotectin concentration.
The fecal calprotectin PETIA was validated on two chemistry analyzers, the Mindray BS-380 (Mindray, Shenzhen, China) and the Cobas 501 (Roche Diagnostics, Basel, Switzerland). The assay is linear in the range 11 μg/g to 2,000 μg/g, with a limit of quantitation of approximately 10 μg/g. No antigen excess hook effect was observed up to 10,000 μg/g to 15,000 μg/g depending on the instrument used. The turbidimetric method showed a good agreement with the Bühlmann ELISA. The total coefficient of variation was 3% to 8% in the 50 μg/g to100 μg/g range.
The authors concluded that the fecal calprotectin PETIA, fCal Turbo, is well suited for rapid analysis of fecal calprotectin on Mindray BS-380 or Cobas 501 clinical chemistry analyzers. The test results are concordant with the Bühlmann fecal MRP8/14 ELISA. The study was published in the September 2016 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Uppsala University
Bühlmann Laboratories
Mindray
Roche Diagnostics
Fecal calprotectin assays are widely used to exclude inflammatory bowel disease (IBD) in patients with suspected IBD, but the problem with most of the fecal calprotectin assays is the rather long test-turnaround times, before the results are available to the physician.
Scientists at Uppsala University (Sweden) optimized a particle enhanced turbidimetric immunoassay (PETIA) for fecal calprotectin and validated the assay for two clinical autoanalyzers using routine fecal samples. They compared the PETIA with a commercial enzyme-linked immunosorbent assay (ELISA), known as the Bühlmann fCAL ELISA (Bühlmann Laboratories, Schönenbuch, Switzerland). This new latex based turbidimetric calprotectin assay applies particles coated with anti-human calprotectin (MRP8/14) antibodies: the agglutination is proportional to the calprotectin concentration.
The fecal calprotectin PETIA was validated on two chemistry analyzers, the Mindray BS-380 (Mindray, Shenzhen, China) and the Cobas 501 (Roche Diagnostics, Basel, Switzerland). The assay is linear in the range 11 μg/g to 2,000 μg/g, with a limit of quantitation of approximately 10 μg/g. No antigen excess hook effect was observed up to 10,000 μg/g to 15,000 μg/g depending on the instrument used. The turbidimetric method showed a good agreement with the Bühlmann ELISA. The total coefficient of variation was 3% to 8% in the 50 μg/g to100 μg/g range.
The authors concluded that the fecal calprotectin PETIA, fCal Turbo, is well suited for rapid analysis of fecal calprotectin on Mindray BS-380 or Cobas 501 clinical chemistry analyzers. The test results are concordant with the Bühlmann fecal MRP8/14 ELISA. The study was published in the September 2016 issue of the Journal of Clinical Laboratory Analysis.
Related Links:
Uppsala University
Bühlmann Laboratories
Mindray
Roche Diagnostics
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Portable POCT Blood Gas Analyzer
BD100
New
Next-Generation Sequencing Platform
AXELIOS 1 Platform
Latest Clinical Chem. News
- Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy
- New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
- Biomarker Score Helps Differentiate Takotsubo Syndrome from Myocardial Infarction
- New Biomarker Recommendations Aim to Personalize Stroke Rehabilitation
- Validated Biomarker Blood Test Detects Early Lung Cancer and Supports Risk Assessment
- Machine Learning Model Uses Routine Lab Tests to Support Heart Failure Classification
- NIH-Funded Study Targets Saliva-Based Long COVID Diagnosis
- Multiprotein Plasma Panel Identifies Remission in Vasculitis
- Rapid Urine Biomarker Panel Supports Better Kidney Transplant Decisions
- Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease
- FDA Clears Roche Blood Test for Alzheimer’s Amyloid Pathology Assessment
- Blood Test Markers Could Help Identify Older Adults at Risk of Disability
- Rapid Ferritin Test Enables Iron Deficiency Detection at the Point of Care
- Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40
- Routine Urine Protein Testing Identifies Undiagnosed Chronic Kidney Disease
- Simple Whole-Blood Screen Identifies Elevated Bile Acids Linked to Liver Disease
Channels
Clinical Chemistry
view channel
Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy
Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more
New Blood Biomarker Predicts May Predict Preeclampsia and Fetal Growth Restriction
Preeclampsia and fetal growth restriction are major drivers of stillbirth and serious maternal morbidity, yet clinicians still lack reliable early predictors to guide targeted surveillance.... Read more
Molecular Diagnostics
view channel
Project to Develop Maternal Blood Test for Rapid Fetal Oxygen Deprivation Detection
Intrapartum fetal hypoxia remains difficult to assess with existing monitoring, leaving clinicians to make time-critical decisions with incomplete data. Limited detection and interpretation can contribute... Read more
DPYD Genotyping Assay Supports Safer Fluoropyrimidine Chemotherapy Dosing
Fluoropyrimidine-based chemotherapy can lead to severe toxicity in patients with specific variants in the dihydropyrimidine dehydrogenase (DPYD) gene, making pre-treatment assessment a critical step in... Read more
Hematology
view channel
Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. In older adults, both high and low values have been linked to adverse outcomes, including cognitive... Read more
Biomarker-Guided Framework Aims to Guide Mantle Cell Lymphoma Therapy
Mantle cell lymphoma can follow widely variable courses, from indolent disease to rapidly progressive cancer, complicating initial treatment selection. Many therapeutic decisions still rely on patient... Read more
Microbiology
view channel
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Pathology
view channel
FDA Clearance Expands Digital Pathology Options for Clinical Laboratories
Hamamatsu Photonics K.K. (Hamamatsu, Japan) announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the NanoZoomer S20MD and NanoZoomer S540MD slide scanner systems.... Read more
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read more
Technology
view channel
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read more
Industry
view channel
New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more
